Comparative Pharmacology
Head-to-head clinical analysis: E BASE versus PEDIAMYCIN 400.
Peer-Reviewed Evidence
Head-to-head clinical analysis: E BASE versus PEDIAMYCIN 400.
E-BASE vs PEDIAMYCIN 400
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
E-BASE is a proton pump inhibitor that irreversibly inhibits the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, suppressing gastric acid secretion.
Erythromycin binds to the 50S subunit of the bacterial ribosome and inhibits protein synthesis by blocking the translocation step.
25 mg orally once daily.
400 mg orally every 6 hours for 10 days.
None Documented
None Documented
Terminal elimination half-life is approximately 6-8 hours in adults with normal renal function; may be prolonged in renal impairment.
1.5-2 hours; prolonged in renal impairment (up to 6 hours)
Renal excretion of unchanged drug accounts for approximately 60-70% of elimination; biliary/fecal excretion accounts for 20-30%.
Renal (80-90% unchanged); biliary/fecal (minor, <5%)
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic